Co-Diagnostics to Present Technology Applications at 4th ACTC Liquid Biopsy Conference in Corfu, Greece
October 03 2019 - 6:30AM
Co-Diagnostics, Inc.
(Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today that it
will be presenting liquid biopsy applications of its patented
CoPrimer™ technology at the 4th Advances in Circulating Tumor Cells
(ACTC) conference, “Liquid Biopsy: Latest Advances and Future
Challenges,” held October 2-5 2019 in Corfu, Greece.
Liquid biopsy refers to an array of diagnostic
tools that analyze blood samples—as opposed to tissue—to identify
genetic mutations from “circulating tumor” DNA, or ctDNA, which
indicate the presence of cancer.
The 4th ACTC brings together liquid biopsy
industry leaders, researchers, and clinicians to discuss and share
late-breaking news about circulating tumor cells, ctDNA, related
technologies, and their clinical applications. The conference
website states that “Liquid biopsy is a fascinating and
exponentially growing field and has a tremendous potential to
significantly change the therapeutic strategy in cancer patients,
providing an extremely powerful and reliable non-invasive clinical
tool for the individual molecular profiling of patients in real
time.”
The Company’s presentation is titled “Evaluation
of Cooperative Primers for Rare Allele Detection,” and will be
delivered on October 4 by CEO Dwight Egan.
“The strengths of our CoPrimer real-time qPCR
platform lie in its ability to create incredibly specific multiplex
assays, which greatly facilitates identifying an array of different
mutations via an effective, cost-efficient diagnostic tool,”
remarked Mr. Egan. “With the global economic burden for cancer
estimated by the WHO to be US$1.6 trillion nearly 10 years ago, and
liquid biopsy projected to be worth as much as $12 billion within 6
years, we believe that these markets will welcome the cost saving
advantages afforded by our technology.
“We are thrilled to be able to present the
results of our research into using CoPrimers for liquid biopsy
applications to such prestigious company. Earlier cancer detection
often makes the difference between surviving and succumbing to a
disease that is the second leading cause of death in the United
States, and even the slightest edge in accurate mutation
identification has the potential to save thousands of lives and
millions of dollars in the US alone every year.”
About Co-Diagnostics,
Inc.:Co-Diagnostics, Inc., a Utah corporation, is a
molecular diagnostics company that develops, manufactures and
markets a new, state-of-the-art diagnostics technology. The
Company’s technology is utilized for tests that are designed using
the detection and/or analysis of nucleic acid molecules (DNA or
RNA). The Company also uses its proprietary technology to design
specific tests to locate genetic markers for use in industries
other than infectious disease and license the use of those tests to
specific customers.
Forward-Looking Statements:
This press release contains
forward-looking statements. Forward-looking statements can be
identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company’s liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company’s products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company’s balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities
laws.
Company
Contact:
Andrew
Benson
Head of Investor
Relations
+1
801-438-1036
investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024